Literature DB >> 29428629

Reply by Authors.

.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29428629      PMCID： PMC7332225          DOI： 10.1016/j.juro.2017.11.138

Source DB:  PubMed          Journal:  J Urol        ISSN： 0022-5347            Impact factor:   7.450


× No keyword cloud information.
  5 in total

1.  Prognostic significance of PD-L1 expression on tumor cells and tumor-infiltrating mononuclear cells in upper tract urothelial carcinoma.

Authors:  Bo Zhang; Wei Yu; Xueru Feng; Zheng Zhao; Yu Fan; Yisen Meng; Shuai Hu; Yun Cui; Qun He; Hong Zhang; Dong Li; Zhisong He; Liqun Zhou; Jie Jin; Wenke Han
Journal:  Med Oncol       Date:  2017-04-13       Impact factor: 3.064

Review 2.  Prospects and progress of immunotherapy for bladder cancer.

Authors:  Martin Boegemann; Ahmet Murat Aydin; Aditya Bagrodia; Laura-Maria Krabbe
Journal:  Expert Opin Biol Ther       Date:  2017-08-23       Impact factor: 4.388

Review 3.  Atezolizumab: A PD-L1-Blocking Antibody for Bladder Cancer.

Authors:  Brant A Inman; Thomas A Longo; Sundhar Ramalingam; Michael R Harrison
Journal:  Clin Cancer Res       Date:  2016-11-30       Impact factor: 12.531

4.  Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma.

Authors:  J Bellmunt; S A Mullane; L Werner; A P Fay; M Callea; J J Leow; M E Taplin; T K Choueiri; F S Hodi; G J Freeman; S Signoretti
Journal:  Ann Oncol       Date:  2015-01-18       Impact factor: 32.976

5.  Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.

Authors:  Jonathan E Rosenberg; Jean Hoffman-Censits; Tom Powles; Michiel S van der Heijden; Arjun V Balar; Andrea Necchi; Nancy Dawson; Peter H O'Donnell; Ani Balmanoukian; Yohann Loriot; Sandy Srinivas; Margitta M Retz; Petros Grivas; Richard W Joseph; Matthew D Galsky; Mark T Fleming; Daniel P Petrylak; Jose Luis Perez-Gracia; Howard A Burris; Daniel Castellano; Christina Canil; Joaquim Bellmunt; Dean Bajorin; Dorothee Nickles; Richard Bourgon; Garrett M Frampton; Na Cui; Sanjeev Mariathasan; Oyewale Abidoye; Gregg D Fine; Robert Dreicer
Journal:  Lancet       Date:  2016-03-04       Impact factor: 79.321
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.